Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial
JCO Oncology Practice · 25.06.2024
DOI: 10.1200/op.24.00031 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JCO Oncology Practice, online erschienen am 25.06.2024. Verfasst von Ilana Graetz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA. Hauptthemen laut MEDLINE: Breast Neoplasms, Capecitabine, Medication Adherence, Telemedicine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Oral capecitabine improves convenience compared to intravenous therapies but presents monitoring challenges. We conducted a randomized pilot trial to evaluate a mobile health intervention to remotely monitor capecitabine adherence and patient-reported outcomes (PROs) among women with breast cancer. METHODS Patients with breast cancer prescribed capecitabine, an oral chemotherapy with a complex, cyclical regimen, were randomly assigned to enhanced usual care (EUC) or PRO arm. Participants were asked to use a smart pill bottle to measure adherence (timing and dose) and complete baseline and 90-day follow-up surveys. PRO participants received text messages for missed or incorrect doses and weekly text-based symptom assessments, and their oncologists received alerts for severe symptoms or missed doses. We compared nonadherence (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA.
- Novartis Pharmaceutical Corporation, Atlanta, GA.
- Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
- Department of Radiological Sciences, University of California Irvine, Orange, CA.
- Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
ORCID-Profile: Ilana Graetz, Kristina Byers, Gelareh Sadigh, Keerthi Gogineni, Mylin A Torres
Förderung
- NCI NIH HHS
Zitieren
APA
Graetz, I., Hernandez, S., Arshad, S., Byers, K., Meisel, J., Sadigh, G., Sakach, E. A., Gogineni, K., & Torres, M. A. (2024). Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial. JCO Oncology Practice. https://doi.org/10.1200/op.24.00031
Vancouver
Graetz I, Hernandez S, Arshad S, Byers K, Meisel J, Sadigh G, et al. Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial. JCO Oncology Practice. 2024. doi:10.1200/op.24.00031
BibTeX
@article{Graetz2024,
author = {Graetz, Ilana and Hernandez, Samuel and Arshad, Sara and Byers, Kristina and Meisel, Jane and Sadigh, Gelareh and Sakach, Elizabeth A and Gogineni, Keerthi and Torres, Mylin A},
title = {Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial},
journal = {JCO Oncology Practice},
year = {2024},
doi = {10.1200/op.24.00031}
}
EUVIMED